Thursday, 15 October 2026European Markets

VANTIVA Stock Bullish By 22% In The Last 10 Sessions

Loading stream...

(vianews) - shares of vantiva (cac 40: vanti.pa) rose by a staggering 22.7% in 10 sessions from €0.23 to €0.28 at 04:11 est on thursday, following the last session's downward trend. cac 40 is dropping 0.2% to €7,324.76, after two successive sessions in a row of losses.

about vantiva

vantiva s.a. develops, creates, and delivers products and services for the media and entertainment sectors in france, the united kingdom, rest of europe, the united states, rest of americas, and the asia-pacific. it operates through three segments: technicolor creative studios, dvd services, and connected home. the technicolor creative studios segment offers high-end services to content creators, including visual effects and animation for features films, episodic series, advertising, video games, and other audiovisual content. the dvd services segment replicates, packages, and distributes video game and music cd, dvd, and blu-ray discs; and provides turnkey integrated supply-chain solutions comprising distribution, fulfillment, freight-brokerage, and transportation management services, as well as inventory management and related services. the connected home segment offers a portfolio of broadband and video customer premise equipment, including broadband modems and gateways, digital set-top boxes, and internet of things connected devices for pay-tv operators and network service providers, as well as develops software solutions. the company was formerly known as technicolor sa and changed its name to vantiva s.a. in september 2022. vantiva s.a. was incorporated in 1985 and is headquartered in paris, france.

more news about vantiva (vanti.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com